NICE describes how weight loss drug tirzepatide will be rolled out
The medication will initially be offered only to those people with the highest clinical needs.
Our recommendations help practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.
The medication will initially be offered only to those people with the highest clinical needs.
A new treatment for Duchenne muscular dystrophy (DMD) is set to be available to around 1,700 people in England following positive final draft guidance from NICE published today.
Dr Patterson, a GP working on the frontline of primary care, describes why he is encouraged by NICE's approval of tirzepatide (Mounjaro).
Working alongside people and communities is an essential tool in helping to improve the impact of our guidance and continuing to get the best care to people and communities, fast, while ensuring value for the taxpayer.
Best practice resources for practitioners and commissioners.
Useful sources of information and advice for healthcare professionals, patients, parents and carers.
Summaries of evidence and advice on common health topics (CKS)
Join the NICE Board as a non-executive director and help shape the future of health and social care improvement.
We're seeking 3 experts in health economics, digital health, and commissioning.